Continued Benefit, More Toxicity With Osimertinib-Chemo Continued Benefit, More Toxicity With Osimertinib-Chemo

Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news